Published in Virology on December 06, 2008
Few and far between: how HIV may be evading antibody avidity. PLoS Pathog (2010) 1.94
Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell (2015) 1.02
HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores. J Virol (2012) 1.00
The frantic play of the concealed HIV envelope cytoplasmic tail. Retrovirology (2013) 0.90
Assembly and replication of HIV-1 in T cells with low levels of phosphatidylinositol-(4,5)-bisphosphate. J Virol (2011) 0.89
The Nef-infectivity enigma: mechanisms of enhanced lentiviral infection. Curr HIV Res (2011) 0.88
Vpx complementation of 'non-macrophage tropic' R5 viruses reveals robust entry of infectious HIV-1 cores into macrophages. Retrovirology (2014) 0.81
Strategies to inhibit viral protein nuclear import: HIV-1 as a target. Biochim Biophys Acta (2010) 0.81
Enhanced antagonism of BST-2 by a neurovirulent SIV envelope. J Clin Invest (2016) 0.79
Deletions in the fifth alpha helix of HIV-1 matrix block virus release. Virology (2014) 0.76
Inhibition of HIV Virus by Neutralizing Vhh Attached to Dual Functional Liposomes Encapsulating Dapivirine. Nanoscale Res Lett (2016) 0.75
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 10.36
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A (1990) 8.23
HIV-1 gag proteins: diverse functions in the virus life cycle. Virology (1998) 7.32
Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A (2001) 5.46
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol (2002) 5.20
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc Natl Acad Sci U S A (1996) 4.83
Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol (1991) 4.74
Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1994) 4.28
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell (1995) 4.25
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20
Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci U S A (2006) 4.14
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol (1996) 4.08
Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol (1994) 3.85
The pH independence of mammalian retrovirus infection. J Gen Virol (1990) 3.68
Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J Virol (1994) 3.59
Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol (1998) 3.27
Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol (2004) 3.22
Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc Natl Acad Sci U S A (2003) 3.20
Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J Virol (1996) 3.19
Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells. Proc Natl Acad Sci U S A (1991) 3.18
Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J Virol (1999) 3.13
Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J Virol (1997) 3.07
Assembly and budding of influenza virus. Virus Res (2004) 2.90
Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J (1996) 2.75
Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J Virol (1999) 2.70
The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci U S A (2000) 2.70
AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. Cell (2005) 2.68
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66
Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains. J Virol (1995) 2.59
Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol (2004) 2.47
Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol (2000) 2.27
An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J Cell Biol (1996) 2.06
Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology (1997) 2.02
Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles. J Virol (2000) 2.00
Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol (1993) 1.99
Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity. J Virol (1994) 1.97
Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J Virol (2004) 1.89
Interactions of HIV-1 Gag with assembly cofactors. Biochemistry (2006) 1.83
Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J Virol (2005) 1.77
Lipid rafts and pseudotyping. J Virol (2001) 1.75
A novel nuclear export activity in HIV-1 matrix protein required for viral replication. Nature (1999) 1.67
Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. Proc Natl Acad Sci U S A (2006) 1.63
Targeting of the human immunodeficiency virus type 1 envelope to the trans-Golgi network through binding to TIP47 is required for env incorporation into virions and infectivity. J Virol (2003) 1.54
Role of HIV-1 Gag domains in viral assembly. Biochim Biophys Acta (2003) 1.53
Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein. Virology (1994) 1.52
Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1993) 1.47
Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex. J Mol Biol (2000) 1.44
A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol Biol Cell (2006) 1.38
Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation. J Virol (2002) 1.37
Actin cytoskeletal reorganizations and coreceptor-mediated activation of rac during human immunodeficiency virus-induced cell fusion. J Virol (2004) 1.32
Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag. Virology (2006) 1.30
Comparison of the NMR and X-ray structures of the HIV-1 matrix protein: evidence for conformational changes during viral assembly. Protein Sci (1996) 1.26
Interaction of HIV-1 Gag with the clathrin-associated adaptor AP-2. Virology (2005) 1.25
Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. J Virol (2003) 1.24
Sorting of the respiratory syncytial virus matrix protein into detergent-resistant structures is dependent on cell-surface expression of the glycoproteins. Virology (2002) 1.23
Rapid localization of Gag/GagPol complexes to detergent-resistant membrane during the assembly of human immunodeficiency virus type 1. J Virol (2003) 1.23
A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41. J Virol (2006) 1.22
The cytoplasmic tail of the human respiratory syncytial virus F protein plays critical roles in cellular localization of the F protein and infectious progeny production. J Virol (2006) 1.20
Human immunodeficiency virus type 1 matrix protein assembles on membranes as a hexamer. J Virol (2006) 1.17
Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol (2006) 1.12
Human immunodeficiency virus (HIV) type 1 can superinfect HIV-2-infected cells: pseudotype virions produced with expanded cellular host range. Proc Natl Acad Sci U S A (1992) 1.11
Amphotropic murine leukaemia virus envelope protein is associated with cholesterol-rich microdomains. Virol J (2005) 1.09
Gag regulates association of human immunodeficiency virus type 1 envelope with detergent-resistant membranes. J Virol (2006) 1.06
Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J Virol (2003) 1.03
Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line. J Virol Methods (2000) 1.02
Role of human immunodeficiency virus type 1 matrix phosphorylation in an early postentry step of virus replication. J Virol (2004) 0.94
Properties of wild-type, C-terminally truncated, and chimeric maedi-visna virus glycoprotein and putative pseudotyping of retroviral vector particles. J Virol (2001) 0.90
Mutations that mimic phosphorylation of the HIV-1 matrix protein do not perturb the myristyl switch. Protein Sci (2007) 0.81
Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog (2008) 2.72
Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol (2008) 2.67
Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med (2009) 2.43
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma (2012) 1.48
The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci U S A (2006) 1.39
Human T-cell lymphotropic virus type 1 open reading frame II-encoded p30II is required for in vivo replication: evidence of in vivo reversion. J Virol (2004) 1.37
Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry. J Virol (2008) 1.25
Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. PLoS Pathog (2006) 1.24
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol (2002) 1.16
Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene (2005) 1.15
Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step. PLoS Pathog (2010) 1.14
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood (2013) 1.13
HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood (2005) 1.09
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood (2004) 1.09
Hsp40 facilitates nuclear import of the human immunodeficiency virus type 2 Vpx-mediated preintegration complex. J Virol (2007) 1.08
Identification of the nuclear localization signal of human immunodeficiency virus type 2 Vpx. Virology (2003) 1.07
IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood (2007) 1.06
IL4/PGE2 induction of an enlarged early endosomal compartment in mouse macrophages is Rab5-dependent. Exp Cell Res (2006) 1.06
Post-formulation peptide drug loading of nanostructures for metered control of NF-κB signaling. Biomaterials (2011) 1.04
Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J Virol (2003) 1.03
Human T-lymphotropic virus type-1 p30 alters cell cycle G2 regulation of T lymphocytes to enhance cell survival. Retrovirology (2007) 1.02
Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13(II) is required for viral infectivity in vivo. J Virol (2006) 1.02
Analysis of HIV-2 Vpx by modeling and insertional mutagenesis. Virology (2006) 1.02
Cytolytic nanoparticles attenuate HIV-1 infectivity. Antivir Ther (2012) 1.02
Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood (2004) 1.00
Integrase inhibitors effective against human T-cell leukemia virus type 1. Antimicrob Agents Chemother (2011) 0.97
Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. Blood (2008) 0.95
Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano (2013) 0.95
Acetylation of the human T-cell leukemia virus type 1 Tax oncoprotein by p300 promotes activation of the NF-kappaB pathway. Virology (2009) 0.94
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol (2012) 0.94
Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix. Virology (2007) 0.94
Role of human immunodeficiency virus type 1 matrix phosphorylation in an early postentry step of virus replication. J Virol (2004) 0.94
Vpx is critical for SIVmne infection of pigtail macaques. Retrovirology (2012) 0.93
T-cell activation promotes tumorigenesis in inflammation-associated cancer. Retrovirology (2009) 0.93
The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice. PLoS One (2010) 0.93
Molecular determinants of human T-lymphotropic virus type 1 transmission and spread. Viruses (2011) 0.92
Histone acetyltransferase (HAT) activity of p300 modulates human T lymphotropic virus type 1 p30II-mediated repression of LTR transcriptional activity. Virology (2006) 0.92
Cholesterol dependence of HTLV-I infection. AIDS Res Hum Retroviruses (2005) 0.90
Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. Virology (2008) 0.89
Engraftment and tumorigenesis of HTLV-1 transformed T cell lines in SCID/bg and NOD/SCID mice. Leuk Res (2002) 0.89
Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. Clin Infect Dis (2009) 0.87
Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis. Retrovirology (2012) 0.87
Anti-Vpr activity of a yeast chaperone protein. J Virol (2004) 0.86
Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. Curr Opin Oncol (2002) 0.86
The HTLV-1 hbz antisense gene indirectly promotes tax expression via down-regulation of p30(II) mRNA. Virology (2010) 0.85
Modulation of beta-catenin and E-cadherin interaction by Vpu increases human immunodeficiency virus type 1 particle release. J Virol (2008) 0.84
Alpha interferon restricts human T-lymphotropic virus type 1 and 2 de novo infection through PKR activation. J Virol (2013) 0.84
Interaction of HIV-1 gag and membranes in a cell-free system. Virology (2002) 0.84
Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay. Virology (2007) 0.83
Suppression of human T-cell leukemia virus I gene expression by pokeweed antiviral protein. J Biol Chem (2009) 0.82
Association of primate T-cell lymphotropic virus infection of pig-tailed macaques with high mortality. Virology (2002) 0.81
HIV-2 viral protein X (Vpx) ubiquitination is dispensable for ubiquitin ligase interaction and effects on macrophage infection. Virology (2012) 0.80
In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations. Blood (2005) 0.79
HIV-2 Vpx protein interacts with interferon regulatory factor 5 (IRF5) and inhibits its function. J Biol Chem (2014) 0.79
Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma (2006) 0.78
The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. Leuk Res (2012) 0.78
Targeting HTLV-1 activation of NFκB in mouse models and ATLL patients. Viruses (2011) 0.78
Substitution of HIV Type 1 Nef with HTLV-1 p12. AIDS Res Hum Retroviruses (2004) 0.78
Phosphoprotein P of Rinderpest virus binds to plus sense leader RNA: regulation by phosphorylation. Virus Res (2004) 0.76
HIV-1 determinants of thrombocytopenia at the stage of CD34+ progenitor cell differentiation in vivo lie in the viral envelope gp120 V3 loop region. Virology (2010) 0.75
Conference highlights of the 16th International Conference on Human Retrovirology: HTLV and related retroviruses, 26-30 June 2013, Montreal, Canada. Retrovirology (2014) 0.75